Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alflutinib in advanced NSCLC
NCT02973763Phase 1Terminated
- Sponsor
- Allist Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events. Started Dec 2016; status: terminated.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02973763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973763.